Fate Therapeutics (FATE) Tops Q2 EPS by 7c

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Circle split as Morgan Stanley cuts to Underweight, TD Cowen starts at Buy
• Oiln (OLN) PT Lowered to $20 at Truist Securities
• Amazon surpasses $3 trillion valuation as AI and cloud propel shares